• If you are wondering whether Legend Biotech's current share price still reflects its potential, you are not alone. Many investors are asking the same question after a tough period for the stock.
• Legend Biotech's share price closed at US$17.15, with returns of a 9.5% decline over 7 days, a 20.3% decline over 30 days, a 20.3% decline year to date, a 54.0% decline over 1 year and a 65.5% decline over 3 years. This performance has reshaped how some investors view both its upside and its risks.
• Recent news coverage around Legend Biotech has focused on the company as part of broader discussions about the biotechnology sector and sentiment toward higher risk, research driven businesses. This context helps frame the recent share price moves as investors reassess how they value companies in this space.
• On our checks, Legend Biotech scores 5 out of 6 on valuation, as shown in our valuation scorecard. Next, we will walk through the standard valuation approaches used to assess the stock and then look at a more complete way to think about value that ties everything together.

Approach 1: Legend Biotech Discounted Cash Flow (DCF) Analysis

A DCF model takes estimates of a company’s future cash flows, then discounts them back to today to arrive at an estimate of what the business might be worth per share right now.

For Legend Biotech, the latest twelve month free cash flow is a loss of $203.2 million. Analysts have provided cash flow estimates out to 2028 and, from there, Simply Wall St extrapolates further, with projected free cash flow reaching $1.1b by 2035. These projections, all in $, are fed into a 2 Stage Free Cash Flow to Equity model that separately treats an initial forecast period and a later, steadier phase.

On this basis, the model suggests an estimated intrinsic value of about $122.69 per share, compared with the recent share price of $17.15. That gap equates to an implied 86.0% discount, which points to Legend Biotech trading well below this particular cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Legend Biotech is undervalued by 86.0%. Track this in your watchlist or portfolio, or discover 876 more undervalued stocks based on cash flows.

Approach 2: Legend Biotech Price vs Sales (P/S)

For companies where profits are limited or volatile, investors often look at the Price to Sales ratio because revenue can be a more stable reference point than earnings. A higher P/S ratio is usually linked to stronger growth expectations or lower perceived risk, while a lower P/S ratio can reflect more modest growth assumptions or higher uncertainty.

Legend Biotech currently trades on a P/S ratio of 3.48x. This sits well below the Biotechs industry average P/S of 11.77x and also below the peer group average of 12.21x. To go a step further, Simply Wall St calculates a Fair Ratio of 3.59x for Legend Biotech. This is a proprietary estimate of the P/S multiple that might be reasonable for the company, based on factors such as its revenue growth outlook, profit margins, industry, market cap and key risks.

Compared with simple industry or peer averages, this Fair Ratio gives a more tailored benchmark because it adjusts for the company’s own characteristics rather than assuming all biotechs should trade on the same multiple. With Legend Biotech’s current P/S of 3.48x versus a Fair Ratio of 3.59x, the shares screen slightly below that tailored estimate.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1424 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Legend Biotech Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company tied directly to your numbers like fair value, future revenue, earnings and margins.

On Simply Wall St, Narratives live on the Community page and give you a clear link from Legend Biotech’s business story to a forecast and then to a fair value that you can compare with the current share price to help decide whether you want to buy, hold, or sell.

Because Narratives on the platform update when new information such as news or earnings arrives, your Legend Biotech view does not stay static. It evolves as the facts change while still keeping your original assumptions and logic visible.

For example, one Legend Biotech Narrative on Simply Wall St might assume a relatively low fair value based on cautious revenue and margin assumptions, while another Narrative might set a much higher fair value based on stronger expectations for future revenue and profitability, and both are reflected directly in those authors’ estimates and price versus fair value views.

Do you think there's more to the story for Legend Biotech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.